vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Climb Global Solutions, Inc. (CLMB). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $182.4M, roughly 1.1× Climb Global Solutions, Inc.). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs -14.6%, a 16.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 32.1%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 40.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
AXSM vs CLMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $182.4M |
| Net Profit | $-28.6M | $3.3M |
| Gross Margin | — | 14.5% |
| Operating Margin | -13.8% | 2.1% |
| Net Margin | -14.6% | 1.8% |
| Revenue YoY | 65.0% | 32.1% |
| Net Profit YoY | 61.9% | -9.5% |
| EPS (diluted) | $-0.55 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $182.4M | ||
| Q4 25 | $196.0M | $193.8M | ||
| Q3 25 | $171.0M | $161.3M | ||
| Q2 25 | $150.0M | $159.3M | ||
| Q1 25 | $121.5M | $138.0M | ||
| Q4 24 | $118.8M | $161.8M | ||
| Q3 24 | $104.8M | $119.3M | ||
| Q2 24 | $87.2M | $92.1M |
| Q1 26 | — | $3.3M | ||
| Q4 25 | $-28.6M | $7.0M | ||
| Q3 25 | $-47.2M | $4.7M | ||
| Q2 25 | $-48.0M | $6.0M | ||
| Q1 25 | $-59.4M | $3.7M | ||
| Q4 24 | $-74.9M | $7.0M | ||
| Q3 24 | $-64.6M | $5.5M | ||
| Q2 24 | $-79.3M | $3.4M |
| Q1 26 | — | 14.5% | ||
| Q4 25 | — | 15.4% | ||
| Q3 25 | — | 15.9% | ||
| Q2 25 | — | 16.5% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 20.3% | ||
| Q2 24 | — | 20.2% |
| Q1 26 | — | 2.1% | ||
| Q4 25 | -13.8% | 4.9% | ||
| Q3 25 | -27.0% | 4.3% | ||
| Q2 25 | -24.5% | 5.0% | ||
| Q1 25 | -46.9% | 3.5% | ||
| Q4 24 | -61.1% | 7.2% | ||
| Q3 24 | -59.8% | 7.1% | ||
| Q2 24 | -89.5% | 4.6% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | -14.6% | 3.6% | ||
| Q3 25 | -27.6% | 2.9% | ||
| Q2 25 | -32.0% | 3.7% | ||
| Q1 25 | -48.9% | 2.7% | ||
| Q4 24 | -63.1% | 4.3% | ||
| Q3 24 | -61.7% | 4.6% | ||
| Q2 24 | -91.0% | 3.7% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $-0.55 | $1.51 | ||
| Q3 25 | $-0.94 | $1.02 | ||
| Q2 25 | $-0.97 | $1.30 | ||
| Q1 25 | $-1.22 | $0.81 | ||
| Q4 24 | $-1.54 | $1.52 | ||
| Q3 24 | $-1.34 | $1.19 | ||
| Q2 24 | $-1.67 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $41.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $118.4M |
| Total Assets | $689.8M | $458.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $41.8M | ||
| Q4 25 | $322.9M | $36.6M | ||
| Q3 25 | $325.3M | $49.8M | ||
| Q2 25 | $303.0M | $28.6M | ||
| Q1 25 | $300.9M | $32.5M | ||
| Q4 24 | $315.4M | $29.8M | ||
| Q3 24 | $327.3M | $22.1M | ||
| Q2 24 | $315.7M | $48.4M |
| Q1 26 | — | $118.4M | ||
| Q4 25 | $88.3M | $116.6M | ||
| Q3 25 | $73.7M | $109.3M | ||
| Q2 25 | $73.1M | $105.2M | ||
| Q1 25 | $53.2M | $95.6M | ||
| Q4 24 | $57.0M | $90.6M | ||
| Q3 24 | $92.9M | $87.7M | ||
| Q2 24 | $102.9M | $79.8M |
| Q1 26 | — | $458.8M | ||
| Q4 25 | $689.8M | $460.2M | ||
| Q3 25 | $669.3M | $376.1M | ||
| Q2 25 | $639.8M | $420.7M | ||
| Q1 25 | $596.7M | $370.1M | ||
| Q4 24 | $568.5M | $469.2M | ||
| Q3 24 | $561.5M | $371.9M | ||
| Q2 24 | $548.2M | $302.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-11.9M | ||
| Q3 25 | $1.0M | $22.2M | ||
| Q2 25 | $-32.4M | $-2.2M | ||
| Q1 25 | $-43.4M | $8.5M | ||
| Q4 24 | $-26.2M | $16.0M | ||
| Q3 24 | $-18.6M | $-3.6M | ||
| Q2 24 | $-30.1M | $7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -1.70× | ||
| Q3 25 | — | 4.73× | ||
| Q2 25 | — | -0.37× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | -0.66× | ||
| Q2 24 | — | 2.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
